Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics (BIOCART-HM)

Assistance Publique - Hôpitaux de Paris

Status

Not yet enrolling

Conditions

Hematologic Diseases

Study type

Observational

Funder types

Other

Identifiers

NCT04209829

APHP190678

Details and patient eligibility

About

Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells, T cells whose receptor has been genetically modified, is based on improving the immune response against the tumor. This approach is promising for patients with hematologic malignancies refractory to chemotherapy. Despite impressive results, too many patients are relapsing. The reasons for the relapse, after the injection of CAR T cells, need to be explored. In this context of newly introduced therapeutics, it is essential to better understand the factors associated with the response to treatment with CAR T Cells, especially the characteristics of the tumor and its microenvironment.

The objective of this study is to understand the role of tumor biology, and its microenvironment, in the response to CAR-T Cells therapy in patients with hematologic malignancies

Enrollment

600 estimated patients

Sex

All

Ages

15+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patient with hematological malignancy (lymphoma, ALL, MM)
patient integrated into a CAR-T Cells program treatment
patient aged 15 years or over
patient having signed a written consent; as well as his legal representative if <18 years old

Exclusion criteria